Melatonin Supplementation in Postmenopausal Women With H. Pylori-associated Dyspepsia
Melatonin Supplementation in Postmenopausal Women With H. Pylori-associated Dyspepsia
Background: The aim of the study was to assess the role of melatonin in chronic dyspepsia in
 this group of women, with consideration of Helicobacter infection. Methods: The study
 comprised 152 subjects Including 30 healthy women (group I), 60 women with asymptomatic
 H.pylori infection (group II), and 64 women H. pylori infected with chronic dyspepsia(group
 III). Endoscopic examination, histological assessment of gastric end duodenal mucosa, urease
 breath test(UBT-13C), and serum levels of 17-β-estradiol, follicle stimulating hormone,
 melatonin and urinary concentration of 6-sulfatoxymelatonin were determined by
 immunoenzymatic method. In group III - 14-day antibacterial treatment was introduced with
 pantoprazole, amoxicillin and levofloxacin. Afterward, in 32 women was administered
 placebo(group IIIa), and in 32 women (group IIIb) melatonin at a dose 1 m/morning and 3 mg/at
 bedtime, for six months.
Background:Dyspeptic syndrome in the form of epigastric pain are particularly frequent in
 postmenopausal women. The aim of the study was to assess the role of melatonin in chronic
 dyspepsia in this group of women, with consideration of Helicobacter infection. Methods: The
 study comprised 152 subjects Including 30 healthy women (group I), 60 women with asymptomatic
 H.pylori infection (group II), and 64 women H. pylori infected with chronic dyspepsia(group
 III). Endoscopic examination, histological assessment of gastric end duodenal mucosa, urease
 breath test(UBT-13C), and serum levels of 17-β-estradiol, follicle stimulating hormone,
 melatonin and urinary concentration of 6-sulfatoxymelatonin were determined by
 immunoenzymatic method. In group III - 14-day antibacterial treatment was introduced with
 pantoprazole, amoxicillin and levofloxacin. Afterward, in 32 women was administered
 placebo(group IIIa), and in 32 women (group IIIb) melatonin at a dose 1 m/morning and 3 mg/at
 bedtime, for six months.
Inclusion Criteria:

 Patients with

 -  Epigastric pain of a hunger nature

 -  Pain at night in the epigastric region

 -  Increased appetite

 Exclusion Criteria:

 Patients with

 -  Functional or inflammatory diseases of the gastrointestinal tract liver and pancreas

 -  Metabolic, allergic and mental disease

 -  Hormone replacement therapy